Latest Capital Raises News

Recce Pharmaceuticals secured A$4 million through an institutional placement and launched a Share Purchase Plan to raise up to an additional A$4 million, bolstering funds for commercial licensing and ongoing clinical programs.

TerraCom signals operational recovery with improved coal sales guidance and cost reductions at Blair Athol, while advancing leadership appointments and strategic reviews.

SIV Capital has been advised by the ASX of a significant risk that it will fail to meet key listing requirements, prompting the company to explore alternative paths forward.

1414 Degrees offers bonus Loyalty Options to shareholders alongside a $8.45 million capital raise aimed at advancing its clean energy projects, including the Aurora Energy Precinct and SiNTL commercialisation.

Alliance Nickel has begun vat leach testing on a bulk sample from its NiWest project, targeting a significant reduction in capital costs by replacing heap leaching with a lower-cost atmospheric process. Results are expected by late Q3 2026 and could reshape the project’s economics.

Skin Elements Limited has secured a $900,000 placement at a 25% discount to recent prices, bolstering its balance sheet to advance its natural biotechnology product range. The company also appointed Rod Nicholas as non-executive chairman and engaged Phoenix Global Investments for investor relations.

CZR Resources (ASX:CZR) has launched a recommended all-scrip takeover bid for Zuleika Gold (ASX:ZAG), valuing the company at $44.8 million and offering a significant premium to Zuleika shareholders.

Ioneer Ltd has been conditionally awarded a long-term land lease by the U.S. Army to establish a critical boron processing facility at the Tooele Army Depot in Utah, marking a significant step in securing domestic defense supply chains.

Pengana Capital Group has successfully closed the $267 million initial public offering for its AI Private Opportunities Trust, marking a significant expansion in its fund management portfolio. The new trust is set to begin trading on the ASX on 2 July 2026.

TruScreen Group has completed a substantially oversubscribed NZ$2.9 million rights issue, boosting total capital raised to over NZ$4 million. The funds are set to support the company’s global expansion in cervical screening technology.

Pacific Edge reported a $35.8 million loss in FY26 amid a 47% revenue drop following Medicare coverage loss, but a draft Medicare policy and $36.1 million capital raise set the stage for recovery.

Control Bionics has locked in $9.5 million through a discounted share placement, complemented by a $0.5 million Share Purchase Plan, to back its commercial growth and technology development.